[go: up one dir, main page]

WO2008138968A3 - Forme posologique comprenant de la 10-[(3s)-1-azabicyclo [2.2.2] oct-3-ylméthyl] - 10h-phénothiazine pour administration orale d'une dose quotidienne de 1mg à 3 mg - Google Patents

Forme posologique comprenant de la 10-[(3s)-1-azabicyclo [2.2.2] oct-3-ylméthyl] - 10h-phénothiazine pour administration orale d'une dose quotidienne de 1mg à 3 mg Download PDF

Info

Publication number
WO2008138968A3
WO2008138968A3 PCT/EP2008/055971 EP2008055971W WO2008138968A3 WO 2008138968 A3 WO2008138968 A3 WO 2008138968A3 EP 2008055971 W EP2008055971 W EP 2008055971W WO 2008138968 A3 WO2008138968 A3 WO 2008138968A3
Authority
WO
WIPO (PCT)
Prior art keywords
azabicyclo
phenothiazine
ylmethyl
oct
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/055971
Other languages
English (en)
Other versions
WO2008138968A4 (fr
WO2008138968A2 (fr
Inventor
Thierry Clerc
Alain Delarue
Christophe Przybylski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of WO2008138968A2 publication Critical patent/WO2008138968A2/fr
Publication of WO2008138968A3 publication Critical patent/WO2008138968A3/fr
Publication of WO2008138968A4 publication Critical patent/WO2008138968A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur une forme posologique comprenant de la 10-[(3S)-1-azabicyclo [2.2.2] oct-3-ylméthyl] - 10H-phénothiazine, ou au moins l'un de ses sels pharmacocompatibles, et caractérisée en ce qu'elle se présente sous une forme appropriée à l'administration orale d'une dose quotidienne de 1mg à 3 mg, et à son incorporation à un médicament prévenant ou traitant des troubles allergiques, et plus particulièrement la rhinite
PCT/EP2008/055971 2007-05-15 2008-05-15 Forme posologique comprenant de la 10-[(3s)-1-azabicyclo [2.2.2] oct-3-ylméthyl] - 10h-phénothiazine pour administration orale d'une dose quotidienne de 1mg à 3 mg Ceased WO2008138968A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0755075 2007-05-15
FR0755075A FR2916142A1 (fr) 2007-05-15 2007-05-15 Forme pharmaceutique comprenant du (10-[(3s)-1-azabicyclo [2.2.2]oct-3-ylmethyl]-10h-phenothiazine se presentant sous une forme appropriee pour l'administration d'unde dose journaliere comprise entre 1 et 3 mg

Publications (3)

Publication Number Publication Date
WO2008138968A2 WO2008138968A2 (fr) 2008-11-20
WO2008138968A3 true WO2008138968A3 (fr) 2009-05-22
WO2008138968A4 WO2008138968A4 (fr) 2009-07-02

Family

ID=38752476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055971 Ceased WO2008138968A2 (fr) 2007-05-15 2008-05-15 Forme posologique comprenant de la 10-[(3s)-1-azabicyclo [2.2.2] oct-3-ylméthyl] - 10h-phénothiazine pour administration orale d'une dose quotidienne de 1mg à 3 mg

Country Status (4)

Country Link
AR (1) AR066587A1 (fr)
FR (1) FR2916142A1 (fr)
TW (1) TW200906417A (fr)
WO (1) WO2008138968A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099995A1 (fr) * 2017-11-17 2019-05-23 Neurana Pharmaceuticals, Inc. Méthodes d'administration de tolpérisone

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089860A1 (fr) * 1982-03-05 1983-09-28 Pharmuka Laboratoires Isomère lévogyre de la méquitazine, son procédé de préparation et médicaments le contenant
JPH07188040A (ja) * 1993-12-27 1995-07-25 Taisho Pharmaceut Co Ltd 鼻炎治療用組成物
FR2772029A1 (fr) * 1997-12-08 1999-06-11 Pf Medicament Procede de preparation de la mequitazine et nouvel intermediaire de synthese
JP2000191536A (ja) * 1998-10-20 2000-07-11 Taisho Pharmaceut Co Ltd メキタジン配合内服固形製剤
WO2005037245A2 (fr) * 2003-10-21 2005-04-28 Direct-Haler A/S Medication a administration par voies multiples, servant a traiter une rhinite et un asthme
JP2006096749A (ja) * 2004-08-31 2006-04-13 Takeda Chem Ind Ltd 感冒用医薬組成物
WO2007085652A1 (fr) * 2006-01-30 2007-08-02 Pierre Fabre Medicament Utilisation de l'enantiomere (s) de la mequitazine pour la preparation d'un medicament, tout en limitant la toxicite genomique

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089860A1 (fr) * 1982-03-05 1983-09-28 Pharmuka Laboratoires Isomère lévogyre de la méquitazine, son procédé de préparation et médicaments le contenant
JPH07188040A (ja) * 1993-12-27 1995-07-25 Taisho Pharmaceut Co Ltd 鼻炎治療用組成物
FR2772029A1 (fr) * 1997-12-08 1999-06-11 Pf Medicament Procede de preparation de la mequitazine et nouvel intermediaire de synthese
JP2000191536A (ja) * 1998-10-20 2000-07-11 Taisho Pharmaceut Co Ltd メキタジン配合内服固形製剤
WO2005037245A2 (fr) * 2003-10-21 2005-04-28 Direct-Haler A/S Medication a administration par voies multiples, servant a traiter une rhinite et un asthme
JP2006096749A (ja) * 2004-08-31 2006-04-13 Takeda Chem Ind Ltd 感冒用医薬組成物
WO2007085652A1 (fr) * 2006-01-30 2007-08-02 Pierre Fabre Medicament Utilisation de l'enantiomere (s) de la mequitazine pour la preparation d'un medicament, tout en limitant la toxicite genomique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199538, Derwent World Patents Index; AN 1995-290311, XP002461512 *
DATABASE WPI Week 200050, Derwent World Patents Index; AN 2000-545830, XP002461514 *
DATABASE WPI Week 200628, Derwent World Patents Index; AN 2006-269425, XP002461513 *

Also Published As

Publication number Publication date
AR066587A1 (es) 2009-09-02
WO2008138968A4 (fr) 2009-07-02
TW200906417A (en) 2009-02-16
WO2008138968A2 (fr) 2008-11-20
FR2916142A1 (fr) 2008-11-21

Similar Documents

Publication Publication Date Title
WO2005097125A3 (fr) Methodes et compositions pour le traitement, la prevention ou la gestion des troubles du sommeil et des troubles du sommeil associes a une maladie
WO2008022256A3 (fr) Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
WO2008040534A3 (fr) Formes pharmaceutiques à base de film non muco-adhésif
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2008027350A3 (fr) Compositions pharmaceutiques à base d'acétaminophène
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
TN2010000135A1 (en) Galenical formulations of organic compounds
WO2006116148A3 (fr) Traitement de l'abus de substances toxiques
WO2007009806A3 (fr) Formulations posologiques solides de medicaments narcotiques presentant une adsorption buccale amelioree
WO2009026473A3 (fr) Compositions et formulations thérapeutiques stabilisées
WO2007123848A3 (fr) Préparations thérapeutiques contenant des protéines slrp de classe i modifiées
WO2007131070A3 (fr) Compositions, formes pharmaceutiques et méthodes de traitement des vomissements
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
WO2007145863A3 (fr) Formulation à libération prolongée de naltréxone
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
JP2011500589A5 (fr)
WO2004041190A3 (fr) Compositions comprenant des composes immunomodulateurs pour le traitement et la gestion d'une degeneration maculaire, ainsi que leurs methodes d'utilisation
WO2005082413A3 (fr) Combinaison de ciclesonide et de glycopyrronium
WO2008138968A3 (fr) Forme posologique comprenant de la 10-[(3s)-1-azabicyclo [2.2.2] oct-3-ylméthyl] - 10h-phénothiazine pour administration orale d'une dose quotidienne de 1mg à 3 mg
WO2005094218A3 (fr) Procedes d'utilisation et compositions comprenant des medicaments selectifs inhibiteurs de cytokine pour le traitement et la gestion de troubles du systeme nerveux central
WO2005120518A3 (fr) Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires
WO2004041181A3 (fr) Methodes d'utilisation et compositions contenant des substances medicamenteuses d'inhibition selective des cytokines pour traiter et controler la degenerescence
WO2008079312A3 (fr) Compositions pour traiter une congestion nasale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08750306

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08750306

Country of ref document: EP

Kind code of ref document: A2